Overview

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction

Status:
Not yet recruiting

Trial end date:
2023-02-26

Target enrollment:

Participant gender:

Summary

Renal dysfunction, which comprises 10%-40% of acute heart failure patients (AHF), plays an important role in diuretic resistance mechanism. DR-AHF was designed to demonstrate the effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic resistance.

Phase:

N/A

Details

Lead Sponsor:

Gia Dinh People Hospital

Collaborator:

Otsuka Pharmaceutical Vietnam

Treatments:

Arginine Vasopressin
Diuretics
Sodium Potassium Chloride Symporter Inhibitors
Tolvaptan
Vasopressins